Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines

• Published in: European journal of cancer (1990) Vol. 35; no. 5; pp. 796 - 807
• Main Authors: Tolis, C, Peters, G.J, Ferreira, C.G, Pinedo, H.M, Giaccone, G
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 01.05.1999; Elsevier
• Subjects: Antineoplastic Agents - pharmacology; apoptosis; Apoptosis - drug effects; Biological and medical sciences; Blotting, Western; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; cell cycle; Deoxycytidine - analogs & derivatives; Deoxycytidine - pharmacology; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Flow Cytometry; gemcitabine; Genes, p53; Humans; Immunohistochemistry; lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Medical sciences; Pneumology; topotecan; Topotecan - pharmacology; Tumor Cells, Cultured; Tumors of the respiratory system and mediastinum; lung cancer; apoptosis; gemcitabine; cell cycle; topotecan; Antineoplastic agent; Human; Lung disease; Cell culture; Gemcitabine; Respiratory disease; Topotecan; Malignant tumor; Experimental study; Bronchopulmonary; Chemotherapy; TP53 Gene; Cell cycle; Bronchus disease; Biological effect; Fluorine Organic compounds; Pyrimidine nucleoside; Apoptosis

Apoptosis is a major mode of cell death in response to cytotoxic drug treatment. A correlation between induction of apoptosis and chemosensitivity has been documented in some preclinical models. Topotecan (a topoisomerase I inhibitor) and gemcitabine (a deoxycytidine analogue), two active new drugs...